Zealand Pharma ASZLDPF 62 Altman Z-Score is 17.29 as of Jun. 26, 2026, which is 70% above its 10-year median of 10.18. GuruFocus rates ZLDPF with a GF Score™ of 62/100 and a GF Value™ of $1,920.24 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 934 Biotechnology companies, Zealand Pharma AS ranks better than 86.19% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 17.55 is strong.
Zealand Pharma AS has a Altman Z-Score of 17.29, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Zealand Pharma AS's Altman Z-Score or its related term are showing as below:
ZLDPF'
s Altman Z-Score Range Over the Past 10 Years
Min: -0.73 Med: 10.18 Max: 50.12
Current: 17.55
During the past 13 years, Zealand Pharma AS's highest Altman Z-Score was 50.12. The lowest was -0.73. And the median was 10.18.
Zealand Pharma AS (OTCPK:ZLDPF) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Zealand Pharma AS Altman Z-Score Related Terms
Zealand Pharma AS Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Zealand Pharma AS's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ZLDPF vs VRTX, REGN, ALNY: Altman Z-Score Comparison
For the Biotechnology subindustry, Zealand Pharma AS's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zealand Pharma AS Altman Z-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zealand Pharma AS's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Zealand Pharma AS's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Zealand Pharma AS's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.9551
+
1.4
*
-0.0233
+
3.3
*
0.4546
+
0.6
*
23.4528
+
1.0
*
0.6038
=
17.29
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Zealand Pharma AS (ZLDPF) has a Altman Z-Score of 17.29 as of Jun. 26, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Zealand Pharma AS and its competitors. This is 70% above median its historical median of 10.18. According to the industry distribution chart, Zealand Pharma AS ranks #129 out of 934 companies in the Biotechnology industry, placing it in the top 13.8%.
Is Zealand Pharma AS's Altman Z-Score too high?
Zealand Pharma AS's current Altman Z-Score of 17.29 is 70% above median its 10-year median of 10.18. The Biotechnology industry median Altman Z-Score is 2.63. Zealand Pharma AS's value of 17.29 is 558.7% above this industry median. Based on the distribution chart, Zealand Pharma AS ranks #129 out of 934 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Zealand Pharma AS has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zealand Pharma AS's Altman Z-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zealand Pharma AS ranks #129 out of 934 companies for Altman Z-Score. This places Zealand Pharma AS in the top 14% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 2.63. Zealand Pharma AS's value of 17.29 is 558.7% above this benchmark. While the company's 10-year median is 10.18 vs. the industry median of 2.63, Zealand Pharma AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Biotechnology company?
The median Altman Z-Score among Biotechnology companies is 2.63, based on 934 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zealand Pharma AS's current Altman Z-Score of 17.29 is 558.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Zealand Pharma AS and its competitors. For the Biotechnology industry, the median Altman Z-Score is 2.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zealand Pharma AS's current Altman Z-Score is 17.29, which is 70% above median its own 10-year median of 10.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zealand Pharma AS stock overvalued right now?
Based on GuruFocus' analysis, Zealand Pharma AS (ZLDPF) is currently considered Possible Value Trap. The stock's GF Value™ is $1,920.24, compared to a current price of $42.89 — trading 97.8% below its estimated fair value. The current Altman Z-Score is 17.29, which is 70% above median its 10-year median of 10.18 and 558.7% above the Biotechnology industry median of 2.63. Zealand Pharma AS's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Zealand Pharma AS (ZLDPF), the current Altman Z-Score is 17.29 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zealand Pharma AS (ZLDPF) Overvalued in 2026?
Based on GuruFocus' analysis, Zealand Pharma AS stock appears to be undervalued.
The current stock price of $42.89 is trading 97.8% below its estimated GF Value™ of $1,920.24.
GuruFocus considers Zealand Pharma AS to be Possible Value Trap.
Key valuation signals for ZLDPF:
Altman Z-Score: 17.29 (70% above median its 10-year median of 10.18)
GF Value™: $1,920.24 vs. price of $42.89 (97.8% below fair value)
Industry Position: 558.7% above the Biotechnology median (#129 of 934)
No single metric tells the full story. See the ZLDPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
62GF Score
Get the complete analysis for ZLDPF
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZLDPF has been successfully added to your 
